Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ferumoxytol Clear all
Completed Phase 4 Interventional Results available

Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI

NCT02893293
View directory record Official record
Conditions
Osteonecrosis
Interventions
Ferumoxytol-enhanced magnetic resonance imaging, Magentic Resonance Imaging
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 3 Interventional

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

NCT00233597
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or oral iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

NCT02678767
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Ferumoxytol
Drug
Lead sponsor
Beau Nakamoto
Other
Eligibility
40 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 19, 2026, 9:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

NCT02791568
View directory record Official record
Conditions
Pregnancy, Obesity, Preeclampsia
Interventions
Ultrasound Scan, MRI Scan, Ferumoxytol
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

NCT03347617
View directory record Official record
Conditions
Glioblastoma
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)

NCT00707876
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

NCT02752191
View directory record Official record
Conditions
Pediatric Congenital Heart Disease
Interventions
ferumoxytol, gadofosveset
Drug
Lead sponsor
Paul Finn
Other
Eligibility
1 Day to 6 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

Iron Indices and Intravenous Ferumoxytol: Time to Steady State

NCT01148745
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol
Drug
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 19, 2026, 9:10 AM EDT
Withdrawn Not applicable Interventional

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

NCT01983371
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Scott Potenta, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model

NCT03678012
View directory record Official record
Conditions
Dental Caries
Interventions
Ferumoxytol/Hydrogen peroxide, Hydrogen Peroxide, Water
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

NCT02499354
View directory record Official record
Conditions
Restless Legs Syndrome, Iron Deficiency Anemia
Interventions
Ferumoxytol intravenous, Ferrous sulfate
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 19, 2026, 9:10 AM EDT
Recruiting Early Phase 1 Interventional

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

NCT04369560
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM)
Diagnostic Test · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 19, 2026, 9:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Imaging of Type 1 Diabetes Progression

NCT01521520
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ferumoxytol
Drug
Lead sponsor
Jason Gaglia
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Early Phase 1 Interventional Results available

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

NCT00978562
View directory record Official record
Conditions
Childhood Brain Neoplasm, Recurrent Childhood Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol Non-Stoichiometric Magnetite, Gadolinium
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
5 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01264679
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

MRA With Feraheme in HHT

NCT02977637
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Feraheme MRI/MRA
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 3 Interventional

A Crossover Safety Study of Ferumoxytol Versus Placebo

NCT00255450
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
41
States / cities
Mobile, Alabama • Phoenix, Arizona • Mountain View, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2008 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

NCT06110494
View directory record Official record
Conditions
Apical Periodontitis, Pulp Disease, Dental
Interventions
Iron oxide nanoparticles treatment Ferumoxytol/H2O2, NaOCl, NaCl, supplementary irrigation
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 19, 2026, 9:10 AM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

NCT03280277
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 19, 2026, 9:10 AM EDT
Withdrawn Not applicable Interventional

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

NCT01663090
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Ferumoxytol
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

NCT01542879
View directory record Official record
Conditions
Cancer
Interventions
WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol, 18-F-FDG PET/MR scan
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 40 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

NCT01052779
View directory record Official record
Conditions
Iron Deficiency, Anemia, Kidney Disease
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Tempe, Arizona • Chula Vista, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 19, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 19, 2026, 9:10 AM EDT
Completed No phase listed Observational

Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI

NCT03266848
View directory record Official record
Conditions
Cerebrovascular Disorders
Interventions
Quantitative Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
Theranano LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 19, 2026, 9:10 AM EDT